Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Retained Earnings (2016 - 2025)

Guided Therapeutics' Retained Earnings history spans 16 years, with the latest figure at -$155.8 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 1.83% year-over-year to -$155.8 million; the TTM value through Sep 2025 reached -$155.8 million, down 1.83%, while the annual FY2024 figure was -$153.7 million, 1.71% down from the prior year.
  • Retained Earnings for Q3 2025 was -$155.8 million at Guided Therapeutics, down from -$155.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$140.6 million in Q1 2021 and bottomed at -$155.8 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$149.9 million (2023), against an average of -$148.6 million.
  • The largest annual shift saw Retained Earnings crashed 1046546.38% in 2021 before it dropped 1.57% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$142.4 million in 2021, then decreased by 3.49% to -$147.4 million in 2022, then dropped by 2.55% to -$151.1 million in 2023, then fell by 1.71% to -$153.7 million in 2024, then decreased by 1.37% to -$155.8 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Retained Earnings are -$155.8 million (Q3 2025), -$155.0 million (Q2 2025), and -$154.2 million (Q1 2025).